DEF 14A: Immunome, Inc. Announces Details for 2024 Annual Stockholders Meeting

Immunome, Inc. has scheduled its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as the company's independent accounting firm.

Summary

• Immunome, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, at 8:30 a.m. Pacific Time.
• The meeting will address the election of two Class I directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and any other business properly brought before the meeting.
• Stockholders of record as of April 25, 2024, are eligible to vote.
• The Board of Directors recommends voting 'FOR' the election of the director nominees and 'FOR' the ratification of the accounting firm appointment.
• The company has elected to provide access to proxy materials over the Internet, with instructions available in the Notice of Internet Availability of Proxy Materials.
• The Board consists of seven members divided into three classes, with Class I directors serving until the 2027 Annual Meeting.
• Clay B Siegall, Ph.D., and Carol A Schafer are the nominees for Class I director positions.
• The Board has determined that Isaac Barchas, Jean-Jacques Bienaim, James Boylan, Carol Schafer, and Sandra Swain, M.D. are independent directors.
• In 2023, the Board held 14 meetings, the Audit Committee held five meetings, the Compensation Committee held five meetings, and the Nominating Committee held four meetings.
• Ernst & Young LLP has served as Immunome's independent registered public accounting firm since 2022.
• The aggregate fees billed by Ernst & Young LLP for the fiscal year ended December 31, 2023, were $727,120, compared to $245,000 in 2022.
• The company's equity compensation plans include the 2020 Plan, the ESPP, and the 2020 MI Plan.
• As of December 31, 2023, there were 7,978,291 securities to be issued upon exercise of outstanding options, warrants, and rights, with a weighted-average exercise price of $6.15.
• There were 4,724,036 securities remaining available for issuance under equity compensation plans as of December 31, 2023.
• Stockholder proposals for the 2025 Annual Meeting must be received no later than December 27, 2024.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The positive aspects include the virtual meeting format and the Board's recommendation to vote in favor of the proposals.

Positives

• The Board is composed of a majority of independent directors, ensuring strong corporate governance.
• The company provides stockholders with convenient online access to proxy materials, reducing costs and conserving resources.
• The virtual format of the Annual Meeting is expected to increase stockholder attendance and participation.
• The Audit Committee has pre-approved all audit and non-audit services provided by Ernst & Young LLP, ensuring independence.
• The company has a Code of Business Conduct and Ethics in place, promoting ethical business decisions.

Negatives

• The increase in fees paid to Ernst & Young LLP from 2022 to 2023 may indicate increased complexity in financial reporting or additional scrutiny required due to the Merger and financing activities.
• The company does not have a formal diversity policy in place, although the Nominating Committee considers diversity in evaluating director nominees.

Risks

• Failure to ratify the appointment of Ernst & Young LLP could require the Audit Committee to reconsider its selection, potentially leading to increased costs and disruption.
• The company's success depends on attracting and retaining qualified personnel, including executive officers and directors.
• The company's stock price could be negatively impacted if stockholders do not support the Board's recommendations on director elections or other proposals.
• The company's future performance is subject to various risks and uncertainties, including those related to the development and commercialization of its products.

Future Outlook

The Board is not aware of any other matters to be brought before the meeting.

Management Comments

• We believe that hosting the Annual Meeting virtually will enable greater stockholder attendance and participation and improves our ability to communicate more effectively with our stockholders.
• Your vote is important. Whether or not you plan to attend virtually the Annual Meeting, we hope you will vote as soon as possible.

Industry Context

Proxy statements are standard documents for publicly traded companies, providing stockholders with information necessary to make informed decisions on key governance matters. The virtual meeting format reflects a growing trend in corporate governance to enhance accessibility and reduce costs.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity awards, appears to be in line with industry standards for similarly sized biopharmaceutical companies.
• The company's engagement of Radford/Aon as a compensation consultant is a common practice among public companies to ensure competitive and fair executive compensation.
• The company's Board diversity matrix provides transparency on the demographic composition of the Board, aligning with Nasdaq's disclosure requirements.

Management Changes

Related Party Transactions

• Clay B. Siegall, Ph.D., President, CEO and Chairman of the Company, purchased 169,204 shares for $999,995.64.
• Bruce Turner, M.D., Ph.D., Chief Strategy Officer of the Company, purchased 42,300 shares for $249,993.00.
• Michael Rapp, Former Chairman of the Company, purchased 253,806 shares for $1,499,993.46.
• Enavate was granted the right to designate a nominee for election to the Board, who is initially James Boylan, until the earlier to occur of (i) a change of control, (ii) Enavate (or its affiliates) holds less than 6.0% of our outstanding capital stock and (iii) June 29, 2030.
• Redmile and EcoR1 were granted the right to appoint an observer to be present and participate in a non-voting, observer capacity at all meetings of the Board, subject, in each case, to certain exceptions until the earlier to occur of (x) a change of control, (y) Redmile or EcoR1, respectively, holds less than 7.5% of our outstanding capital stock and (z) June 29, 2028.

Stakeholder Impact

• Stockholders are provided with the opportunity to vote on key governance matters, influencing the direction of the company.
• Employees are eligible to participate in equity compensation plans, aligning their interests with those of the stockholders.
• The company's financial performance and strategic decisions impact the value of stockholders' investments.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 12, 2024, and announce the voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, Ernst & Young, Audit Committee, Executive Compensation, Stockholders, Immunome, Governance, Merger